Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma

被引:3
|
作者
Amini, Behrang [1 ]
Nakache, Yves-Paul N. [2 ]
Nardo, Lorenzo [2 ]
Manasanch, Elisabet E. [3 ]
Sun, Jia [4 ]
Lenchik, Leon [5 ]
Boutin, Robert D. [6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Musculoskeletal Imaging, 1515 Holcombe Blvd,Unit 1475, Houston, TX 77030 USA
[2] Univ Calif Davis, Dept Radiol, Davis, CA 95616 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[5] Wake Forest Sch Med, Dept Diagnost Radiol, Winston Salem, NC 27101 USA
[6] Stanford Univ, Dept Diagnost Radiol, Stanford, CA 94305 USA
关键词
Multiple myeloma; Smoldering myeloma; FDG PET; CT; ABDOMINAL COMPUTED-TOMOGRAPHY; BODY-COMPOSITION; F-18-FDG PET/CT; SKELETAL-MUSCLE; ADIPOSE-TISSUE; SURVIVAL; RISK; SARCOPENIA; DIAGNOSIS; TOXICITY;
D O I
10.1007/s00256-020-03529-2
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objective To determine association of body composition measurements on CT and PET with progression of smoldering myeloma to multiple myeloma. Methods A retrospective cohort study in 65 patients with smoldering myeloma and PET/CT at diagnosis was performed at a tertiary cancer center. Subjects were between 38 and 87 years of age (mean 64) and included 37 males. Primary outcome was progression-free survival as a function of bone, fat, and muscle metrics on CT and PET (measured at the level of L4 pedicles) and clinical confounders. CT metrics included attenuation of L4 and retroperitoneal fat and various indices derived from the psoas muscle. PET measures included SUV(max)and SUV(mean)of L4, retroperitoneal fat, and psoas. Cox proportional hazards modeling was performed with entry and retention criteria ofp < 0.1 andp < 0.05, respectively. Results SUV(max)and SUV(mean)were associated for each compartment (R-2 = 0.78-0.84), and SUVmean(SUV) was used for subsequent analyses. SUV of the L4 vertebral body was associated with attenuation of the L4 vertebral body (p = 0.0032). There was no association between SUV and CT for muscle and fat compartments. In the subset of patients with bone marrow biopsy results (n = 43), there was no association between SUV of L4 and plasma cell concentration on core biopsy or flow cytometry (p = 0.089 and 0.072, respectively). The final Cox model showed association with albumin (HR 0.29, 95%CI 0.088-0.93,p = 0.038), M protein (HR 1.31, 95%CI 1.021-1.68,p = 0.034), and SUV of L4 (HR 1.99, 95%CI 1.037-3.82,p = 0.039). Conclusion SUV of L4 is a prognostic indicator in patients with smoldering myeloma.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 50 条
  • [1] Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma
    Behrang Amini
    Yves-Paul N. Nakache
    Lorenzo Nardo
    Elisabet E. Manasanch
    Jia Sun
    Leon Lenchik
    Robert D. Boutin
    [J]. Skeletal Radiology, 2021, 50 : 79 - 85
  • [2] FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE MYELOMA INTO SYMPTOMATIC DISEASE
    Zamagni, E.
    Nanni, C.
    Gay, F.
    Pezzi, A.
    Patriarca, F.
    Bello, M.
    Rambaldi, I.
    Tacchetti, P.
    Hillengass, J.
    Gamberi, B.
    Pantani, L.
    Magarotto, V.
    Versari, A.
    Offidani, M.
    Zannetti, B.
    Carobolante, F.
    Balma, M.
    Mansueto, G.
    Englaro, E.
    Mancuso, K.
    Dimitrakopoulou-Strauss, A.
    Rocchi, S.
    Fard, N.
    Marzocchi, G.
    Palumbo, A.
    Fanti, S.
    Cavo, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 31 - 32
  • [3] FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE MYELOMA INTO SYMPTOMATIC DISEASE
    Zamagni, E.
    Nanni, C.
    Gay, F.
    Pezzi, A.
    Patriarca, F.
    Bello, M.
    Rambaldi, I.
    Tacchetti, P.
    Hillengass, J.
    Gamberi, B.
    Pantani, L.
    Magarotto, V.
    Versari, A.
    Offidani, M.
    Zannetti, B.
    Carobolante, F.
    Menga, M.
    Mansueto, G.
    Englaro, E.
    Mancuso, K.
    Dimitrakopoulou-Strauss, A.
    Rocchi, S.
    Fard, N.
    Marzocchi, G.
    Palumbo, A.
    Fanti, S.
    Cavo, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 80 - 80
  • [4] PET/CT and Smoldering Multiple Myeloma
    Pappas, Virginia
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 26N - 26N
  • [5] Prognostic Factors Associated With Progression of Smoldering Multiple Myeloma to Symptomatic Form
    Rago, Angela
    Grammatico, Sara
    Za, Tommaso
    Levi, Anna
    Mecarocci, Sergio
    Siniscalchi, Agostina
    De Rosa, Luca
    Felici, Stefano
    Bongarzoni, Velia
    Piccioni, Anna Lina
    La Verde, Giacinto
    Pisani, Francesco
    Franceschini, Luca
    Paviglianiti, Anna Lisa
    Caravita, Tommaso
    Petrucci, Maria Teresa
    De Stefano, Valerio
    Cimino, Giuseppe
    [J]. CANCER, 2012, 118 (22) : 5544 - 5549
  • [6] Assessment of uptake of FDG in the whole bone marrow of multiple myeloma and smoldering multiple myeloma patients through a novel method of PET/CT quantification: comparison with a control group
    Zadeh, Mahdi Zirakchian
    Ostergaard, Brian
    Raynor, William
    Ayubcha, Cyrus
    Acosta-Montenegro, Oswaldo
    Yellanki, Dani
    Taghvaei, Raheleh
    Gerke, Oke
    Constantinescu, Caius
    Werner, Thomas
    Zhuang, Hongming
    Hoilund-Carlsen, Poul Flemming
    Alavi, Abass
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [7] 18F-FDG PET/CT can be used to predict progression in smoldering multiple myeloma patients
    Visram, Alissa
    Rajkumar, Vincent
    Kumar, Shaji
    Broski, Stephen
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S134 - S134
  • [8] Measuring bone marrow activity with FDG-PET in multiple myeloma, smoldering myeloma, and healthy subjects
    Raynor, William
    Zadeh, Mahdi Zirakchian
    Acosta-Montenegro, Oswaldo
    Khosravi, Mohsen
    Al-Zaghal, Abdullah
    Yellanki, Dani
    Oestergaard, Brian
    Werner, Thomas
    Zhuang, Hongming
    Abildgaard, Niels
    Hoilund-Carlsen, Poul Flemming
    Alavi, Abass
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [9] A RETROSPECTIVE ANALYSIS ON 397 SMOLDERING MULTIPLE MYELOMA (SMM) CASES: PROGNOSTIC FACTORS ASSOCIATED WITH PROGRESSION OF SMOLDERING MULTIPLE MYELOMA TO SYMPTOMATIC FORM
    Rago, A.
    Grammatico, S.
    Za, T.
    Levi, A.
    Mecarocci, S.
    Siniscalchi, A.
    De Rosa, L.
    Corazza, S.
    Felici, S.
    Villiva, N.
    Bongarzoni, V.
    Piccioni, A.
    La Verde, G.
    Pisani, F.
    Franceschini, L.
    Paviglianiti, A.
    Caravita, T.
    Petrucci, M. T.
    De Stefano, V.
    Cimino, G.
    [J]. HAEMATOLOGICA, 2012, 97 : 339 - 339
  • [10] Smouldering multiple myeloma: progression to symptomatic disease predicted by 18F-FDG PET-CT
    Caldarella, C.
    Taralli, S.
    Cocciolillo, F.
    Za, T.
    De Stefano, V.
    Calcagni, M. L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S302 - S302